Trials / Completed
CompletedNCT00394186
A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the Beta-3-Adrenergic Receptor Agonist Solabegron in Subjects With Irritable Bowel Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW427353 | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-08-01
- First posted
- 2006-10-31
- Last updated
- 2009-05-18
Locations
19 sites across 3 countries: Australia, France, Germany
Source: ClinicalTrials.gov record NCT00394186. Inclusion in this directory is not an endorsement.